ADV/IL-12 gene therapy / Roche - LARVOL DELTA

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1 | N=13 | Suspended | Sponsor: The Methodist Hospital Research Institute | Trial completion date: Dec 2025 ➔ Mar 2025 | Recruiting ➔ Suspended | Trial primary completion date: Dec 2024 ➔ Aug 2024

Gene therapy • Metastases • Trial completion date • Trial primary completion date • Trial suspension • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • PD-L1

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: The Methodist Hospital Research Institute | Trial completion date: Dec 2024 ➔ Dec 2025 | Trial primary completion date: Dec 2023 ➔ Dec 2024

Gene therapy • Metastases • Trial completion date • Trial primary completion date • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • PD-L1

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1 | N=16 | Recruiting | Sponsor: The Methodist Hospital Research Institute | Trial completion date: Jun 2024 ➔ Dec 2024 | Trial primary completion date: Jun 2023 ➔ Dec 2023

Gene therapy • Metastases • Trial completion date • Trial primary completion date • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • IL12A • PD-L1

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1; N=16; Recruiting; Sponsor: The Methodist Hospital Research Institute; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • IL12A • PD-L1

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: The Methodist Hospital Research Institute; Initiation date: Jun 2021 ➔ Sep 2021

Clinical • Trial initiation date • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • IL12A • PD-L1

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy (clinicaltrials.gov) - P1; N=16; Not yet recruiting; Sponsor: Eric Bernicker, MD

Clinical • New P1 trial • Gene Therapies • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • CD4 • IL12A • PD-L1